Artificial intelligence (AI) drug discovery corporations Proteina will accelerate the commercialization of next-generation de novo antibody drug design. The plan is to commercialize a drug development model that combines antibody design with large-scale validation.
Proteina said on the 14th that it will invest about 3.4 billion won in ABX Biosciences (hereafter ABX) to become the largest shareholder.
The newly established corporation ABX aims to continuously advance AI model performance to achieve de novo antibody design that surpasses global leading models.
ABX is a corporation established to commercialize the AI antibody design platform "AbGPT-3D (tentative name)," which is being developed through a national project of the Ministry of Science and ICT. Baek Min-gyeong, a Seoul National University professor who led the platform's development, will serve as scientific advisor.
When ABX designs antibody candidates with its AI model, Proteina verifies antibody–antigen interactions with its proprietary single-molecule protein interaction analysis platform (SPID) and generates data.
A "design–validation–retraining" closed-loop (lab-in-the-loop) approach is applied, in which these data feed back into AI model retraining. It is a virtuous cycle where accumulated data are reused to improve AI performance models.
ABX will be responsible for AI model development, while Proteina will handle business development, and the two companies plan to share revenue.